Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech

Signal Genetics and DiagnoCure Announce a US$13.3M Collaboration for the Commercialization of Previstageâ„¢ GCC Colorectal Cancer Staging Test

June 29, 2011 By Bio-Medicine.Org

NEW YORK and QUEBEC CITY, June 29, 2011 /PRNewswire/ — Signal
Genetics, a privately held predictive genetic testing company
focusing on oncology, and DiagnoCure, Inc. (TSX: CUR), a life
sciences company that develops and commercializes high-value cancer
diagnostic tests, today announced a collaboration arrangement
valued at US$13.3M over the first five years.  This
collaboration aims to maximize the commercialization of
Previstage™ GCC Colorectal Cancer Staging Test, and further
develop novel genomic cancer tests in the field of Personalized
Medicine.

Under the definitive agreements underlying the collaboration,
Signal Genetics is granted a worldwide exclusive license to the
Previstage™ GCC Colorectal Cancer Staging Test developed by
DiagnoCure, and acquires DiagnoCure’s U.S. CLIA service laboratory.
These two elements of the transaction combined are valued at a
minimum of US$10.8M over five years, broken down into a US$5.7M
upfront payment for the acquisition of DiagnoCure’s U.S.
laboratory, and a minimum of US$5.1M in annual installments and
royalty payments over the first five years of the license
agreement. In addition, Signal will pay DiagnoCure US$2.5M under an
R&D agreement to advance the development of certain genomic
tests being developed in its Quebec-based laboratories. All
payments will be made in cash.

“Previstage™ GCC has been shown to offer key clinical
information to improve colon cancer management and has an estimated
global market potential of over US$400M,” stated Joe Hernandez, CEO
of Signal Genetics. “We are excited to add it to our product
portfolio.  With our new subsidiary, CC Health LLC, we plan to
expand our sales force and our marketing partnerships to sell the
test nationwide.  Moreover, the R&D agreement provides
Signal and its affiliates access to DiagnoCure’s extensive
experience in developing personalized genomic tests in oncology
that are complementary technologies to the com

‘/>”/>

SOURCE

Related Articles Read More >

Dexcom One
How Dexcom’s portfolio goes beyond highly-anticipated next-gen G7
A portrait of Stryker executive Siddarth Satish
How Stryker includes users for product design in the digital age
A Medtronic HVAD pump opened up to show the inner workings
Medtronic investigates HVAD pump welds after patient deaths
Galien Foundation 2022 nominees
18 of the world’s most innovative medical technologies

DeviceTalks Weekly.

May 20, 2022
DeviceTalks Boston Post-Game – Editors’ Top Moments, Insulet’s Eric Benjamin on future of Omnipod 5
See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

Enewsletter Subscriptions

Enewsletter Subscriptions

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech 100 Index
  • Medical Tubing + Extrusion
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to E-newsletter
  • Attend our Monthly Webinars
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2022 WTWH Media, LLC. All Rights Reserved. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • Med Tech Resources
    • DeviceTalks Tuesdays
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Medical Device Handbook
    • MedTech 100 Index
    • Podcasts
    • Print Subscription
    • The Big 100
    • Webinars / Digital Events
    • Whitepapers
    • Video
  • 2022 Leadership in MedTech
    • 2022 Leadership Voting!
    • 2021 Winners
    • 2020 Winners
  • Women in Medtech